Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Teva Accupril Generic Delayed Until 2007; Pfizer Patent Is Valid, Court Says

This article was originally published in The Pink Sheet Daily

Executive Summary

If upheld on appeal, the decision would eliminate Teva’s 180-day exclusivity period and make a challenge to Pfizer’s own generic moot. A New Jersey federal judge finds there was no inequitable conduct before the PTO regarding Pfizer’s patent for its ACE inhibitor.

You may also be interested in...



Pfizer’s Accupril Patent Case Against Teva Heads Back To Court

A Newark, N.J. federal judge must reconsider whether an Accupril patent is valid and is infringed by Teva’s quinapril generic, an appeals court says.

Pfizer’s Accupril Patent Case Against Teva Heads Back To Court

A Newark, N.J. federal judge must reconsider whether an Accupril patent is valid and is infringed by Teva’s quinapril generic, an appeals court says.

Accupril Generics Come Off The Market Following Preliminary Injunction

Teva and Ranbaxy plan to appeal the district court ruling in favor of Pfizer to the federal appeals court. Pfizer said it will seek damages for lost Accupril sales since the December launch of Teva/Ranbaxy’s quinapril.

Related Content

Topics

UsernamePublicRestriction

Register

PS059873

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel